Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6778148 | 0.96 | PDE5A (0.69) | PDE5APDE6C | |
| SCHEMBL6358551 | 0.92 | PDE5A (0.69) | PDE5APDE6C | |
| SCHEMBL8490684 | 0.90 | PDE5A (0.64) | PDE5APDE6C | |
| SCHEMBL2404505 | 0.88 | PDE5A (0.66) | PDE5APDE6C | |
| SCHEMBL6774043 | 0.88 | PDE5A (0.70) | PDE5APDE6C | |
| SCHEMBL2405075 | 0.86 | PDE5A (0.63) | PDE5APDE6C | |
| SCHEMBL6358922 | 0.86 | PDE5A (0.85) | PDE5APDE6C | |
| SCHEMBL6776131 | 0.84 | PDE5A (0.86) | PDE5APDE6C | |
| SCHEMBL6773144 | 0.82 | PDE5A (0.59) | PDE5APDE6C | |
| SCHEMBL6776828 | 0.81 | PDE5A (1.00) | PDE5APDE6C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212972-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PFIZER INC | 2011-09-01 | — | — | US | disclosed |
| US-20090264413-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PFIZER INC. | 2009-10-22 | — | — | US | disclosed |
| EP-1440709-B1 | Combinations comprising cGMP PDE5 inhibitors. | PFIZER LTD (GB) | 2007-12-05 | — | — | EP | disclosed |
| EP-1149579-B1 | Use of an estrogen agonist/antagonist for treating female sexual dysfunction | PFIZER PROD INC (US) | 2006-12-06 | — | — | EP | disclosed |
| US-20050143367-A1 | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof | PFIZER INC | 2005-06-30 | — | — | US | disclosed |
| US-6809200-B2 | REACTING 5-ACETYL-N-(3-(AMINOCARBONYL)-5-ETHYL-1-(1-ETHYL-3-AZETIDINYL)-1H-PYRAZOL4 -YL)-2-ETHOXYNICOTINAMIDE, IN PRESENCE OF ALCOHOL OR ALKOXY COMPOUND AND A HYDROXIDE TRAPPING AGENT OR BASE | PFIZER INC. | 2004-10-26 | — | — | US | disclosed |
| US-6756373-B1 | SUCH AS 5-(2-BUTOXY-5-IODO-3-PYRIDINYL)-3-ETHYL-2-(2-METHOXY-ETHYL)-2,6-DIHYDRO-7H -PYRAZOLO(4,3-D)PYRIMIDIN-7-ONE; CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS; ERECTILE DYSFUNCTION | PFIZER INC. | 2004-06-29 | — | — | US | disclosed |
| US-20040122010-A1 | Treatment of neuropathy | PFIZER INC | 2004-06-24 | — | — | US | disclosed |
| US-6699991-B2 | A ?ONE-POT? PROCESS IS DESCRIBED HEREIN FOR THE PRODUCTION OF PYRAZOLE COMPOUNDS OF GENERAL FORMULA (II) COMPRISING THE STEPS OF REACTING A COMPOUND OF GENERAL FORMULA (III) WITH AN ACYLATING AGENT IN THE PRESENCE OF A BASE AND AN OPTIONAL | PFIZER INC. | 2004-03-02 | — | — | US | disclosed |
| US-20030162782-A1 | Treatment of neuropathy | UNITED STATES DEPARTMENT OF ENERGY | 2003-08-28 | — | — | US | disclosed |
| US-20030114440-A1 | Compositions and methods of treatment for conditions responsive to testosterone elevation | LEE ANDREW G (US) | 2003-06-19 | — | — | US | disclosed |
| US-20030083228-A1 | Treatments for female sexual dysfunction and methods for identifying compounds useful for treating female sexual dysfunction | CARPINO PHILIP A (US) | 2003-05-01 | — | — | US | disclosed |
| US-6512002-B2 | Treating timidity and enhancing libido in postmenopausal women, or treating male sexual dysfunction by administering to a patient in need thereof an effective amount of an estrogen agonist/antagonist | PFIZER INC. | 2003-01-28 | — | — | US | disclosed |
| US-20020173502-A1 | Pharmaceutically active compounds | PFIZER INC | 2002-11-21 | — | — | US | disclosed |
| US-20020111498-A1 | Novel process for the preparation of pyrazoles | JAMES HARRIS LAURENCE (GB) | 2002-08-15 | — | — | US | disclosed |
| US-6407259-B1 | REACTING DIETHER COMPOUND WITH ACYLATING AGENT COMPRISING ACID ANHYDRIDE OR ACID HALIDE DERIVATIVE TO FORM PYRAZOLE DERIVATIVE | PFIZER INC. | 2002-06-18 | — | — | US | disclosed |
| US-20020038024-A1 | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof | PFIZER INC. | 2002-03-28 | — | — | US | disclosed |
| US-20020022732-A1 | Novel process for the preparation of pyrazoles | PFIZER INC. | 2002-02-21 | — | — | US | disclosed |
| US-20010044434-A1 | Compositions and methods of treatment for conditions responsive to testosterone elevation | LEE ANDREW G (US) | 2001-11-22 | — | — | US | disclosed |
| EP-1129706-A2 | Use of cGMP PDE5 inhibitors for the treatment of neuropathy | Pfizer Limited (GB) | 2001-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020038024-A1 | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof | DPYD, HPRT1, SAMHD1 | PDE5A 1809/4885PDE6C 1920/4885 |
| US-20050143367-A1 | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof | NOX4, VKORC1, DPYD | PDE5A 1588/4885PDE6C 1377/4885 |
| US-20040122010-A1 | Treatment of neuropathy | PDE5A, PDE3A, PDE2A | PDE5A 1/4885PDE6C 9/4885 |
| US-20030162782-A1 | Treatment of neuropathy | PDE5A, PDE3A, PDE2A | PDE5A 1/4885PDE6C 9/4885 |
| US-20020173502-A1 | Pharmaceutically active compounds | PDE5A, PDE3A, PDE3B | PDE5A 1/4885PDE6C 20/4885 |
| US-20030114440-A1 | Compositions and methods of treatment for conditions responsive to testosterone elevation | PDE3B, PDE3A, SHBG | PDE5A 4/4885PDE6C 11/4885 |
| US-20020022732-A1 | Novel process for the preparation of pyrazoles | NAT1, CYP2F1, CYP51A1 | PDE5A 1067/4885PDE6C 4116/4885 |
| US-20030083228-A1 | Treatments for female sexual dysfunction and methods for identifying compounds useful for treating female sexual dysfunction | MC1R, MCHR2, MC3R | PDE5A 208/4885PDE6C 607/4885 |
| US-20010044434-A1 | Compositions and methods of treatment for conditions responsive to testosterone elevation | PDE3B, PDE3A, SHBG | PDE5A 4/4885PDE6C 11/4885 |
| US-20020111498-A1 | Novel process for the preparation of pyrazoles | NAT1, CYP2F1, CYP51A1 | PDE5A 1067/4885PDE6C 4116/4885 |
| US-20090264413-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PDE3A, PDE3B, PDE2A | PDE5A 4/4885PDE6C 20/4885 |
| US-20110212972-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PDE3A, PDE3B, PDE2A | PDE5A 4/4885PDE6C 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.